Fast Facts for Patients: Non-small Cell Lung Cancer with KRAS Mutation PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Fast Facts for Patients: Non-small Cell Lung Cancer with KRAS Mutation PDF full book. Access full book title Fast Facts for Patients: Non-small Cell Lung Cancer with KRAS Mutation by Anne-Marie Baird. Download full books in PDF and EPUB format.
Author: Anne-Marie Baird
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318072494
Category : Medical
Languages : en
Pages : 39
Get Book
Book Description
Non-small cell lung cancer (NSCLC) is one of two main types of lung cancer. Some lung cancers spread to other parts of the body before they are diagnosed. A cancer that has spread is called ‘metastatic’. New lung cancer treatments are being developed that directly target the gene mutations that control how cancers grow and spread. The most important gene mutations in cancer are called ‘driver mutations’. In NSCLC, this includes KRAS mutations, which can be used as targets for treatment. There are new treatments designed for lung cancers with a KRAS mutation that are already available. And more are being developed. Treatments in development are tested in clinical trials. There are several different phases of clinical trials that people with cancer can take part in. This booklet aims to help patients with NSCLC understand their options so that they can talk to their doctors, nurses, and medical team about their cancer and its treatment. Table of Contents: • What is non-small cell lung cancer? • How can lung cancer develop? • What is metastatic NSCLC? • More about genes and cancer • Oncogenes and cancer • Driver mutations and biomarkers • How your doctor knows your cancer is KRAS-positive • More about KRAS • What does having a KRAS-positive cancer mean for me? • Talking to your doctor about your treatment • About clinical trials and research • Finding further information and support
Author: Anne-Marie Baird
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318072494
Category : Medical
Languages : en
Pages : 39
Get Book
Book Description
Non-small cell lung cancer (NSCLC) is one of two main types of lung cancer. Some lung cancers spread to other parts of the body before they are diagnosed. A cancer that has spread is called ‘metastatic’. New lung cancer treatments are being developed that directly target the gene mutations that control how cancers grow and spread. The most important gene mutations in cancer are called ‘driver mutations’. In NSCLC, this includes KRAS mutations, which can be used as targets for treatment. There are new treatments designed for lung cancers with a KRAS mutation that are already available. And more are being developed. Treatments in development are tested in clinical trials. There are several different phases of clinical trials that people with cancer can take part in. This booklet aims to help patients with NSCLC understand their options so that they can talk to their doctors, nurses, and medical team about their cancer and its treatment. Table of Contents: • What is non-small cell lung cancer? • How can lung cancer develop? • What is metastatic NSCLC? • More about genes and cancer • Oncogenes and cancer • Driver mutations and biomarkers • How your doctor knows your cancer is KRAS-positive • More about KRAS • What does having a KRAS-positive cancer mean for me? • Talking to your doctor about your treatment • About clinical trials and research • Finding further information and support
Author: A.-M. Baird
Publisher: Karger Medical and Scientific Publishers
ISBN: 331807277X
Category : Medical
Languages : en
Pages : 39
Get Book
Book Description
Non-small cell lung cancer (NSCLC) is one of two main types of lung cancer. Some lung cancers spread to other parts of the body before they are diagnosed. A cancer that has spread is called ‘metastatic’. New lung cancer treatments are being developed that directly target the gene mutations that control how cancers grow and spread. The most important gene mutations in cancer are called ‘driver mutations’. In NSCLC, this includes KRAS mutations, which can be used as targets for treatment. There are new treatments designed for lung cancers with a KRAS mutation that are already available. And more are being developed. Treatments in development are tested in clinical trials. There are several different phases of clinical trials that people with cancer can take part in. This booklet aims to help patients with NSCLC understand their options so that they can talk to their doctors, nurses, and medical team about their cancer and its treatment. Table of Contents: • What is non-small cell lung cancer? • How can lung cancer develop? • What is metastatic NSCLC? • More about genes and cancer • Oncogenes and cancer • Driver mutations and biomarkers • How your doctor knows your cancer is KRAS-positive • More about KRAS • What does having a KRAS-positive cancer mean for me? • Talking to your doctor about your treatment • About clinical trials and research • Finding further information and support
Author: Mary O'Brien
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318070106
Category : Medical
Languages : en
Pages : 148
Get Book
Book Description
Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Author: Rona Yaeger
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318072907
Category : Medical
Languages : en
Pages : 41
Get Book
Book Description
Colorectal cancer (CRC) is cancer that begins in the colon or rectum of the digestive system. KRAS is a protein that sends signals to cells telling them to divide. In healthy cells, KRAS can be switched on and off. In some cancer cells, gene mutations cause changes in the KRAS protein that mean it is constantly switched on, driving cells to divide. KRAS mutation status can be used to guide treatment decisions. New treatments that target a KRAS mutation have been approved for non-small cell lung cancer and are now being tested for CRC. Other treatments are also being developed.
Author: Stephen Clarke
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318068217
Category : Medical
Languages : en
Pages : 128
Get Book
Book Description
The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology for decades and need a refresher or you are just starting out and need a crash course, this book provides all you need to know about immuno-oncology, concisely summarized. Table of Contents: • Components of the immune system • How cancers evade the immune system • How cancer immunotherapy works • Clinical use of immune checkpoint inhibitors • The future of immuno-oncology
Author: M. O'Brien
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318070882
Category : Medical
Languages : en
Pages : 148
Get Book
Book Description
Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy, and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Author: Virginia Espina
Publisher: Humana Press
ISBN: 9781603272155
Category : Science
Languages : en
Pages : 0
Get Book
Book Description
The next revolution in molecular medicine is the application of molecular profiling to individualized patient therapy. Molecular profiling technology has advanced dramatically, particularly in the field of cancer tissue biomarkers. It is now possible to gather complex genomic and proteomic information from a routine clinical needle biopsy or surgical specimen. In Molecular Profiling : Methods and Protocols, expert researchers in the field focus on the entire process from discovery to commercialization, with practical guides that are not limited to experimental methods. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, as well as essays and guidelines for grants, patents, and commercialization of products related to molecular profiling. Authoritative and practical, Molecular Profiling: Methods and Protocols seeks to aid scientists in understanding the latest advancements in genomics, proteomics, imagining, and bioinformatics.
Author: Philip T. Cagle
Publisher: Springer Science & Business Media
ISBN: 1461431972
Category : Medical
Languages : en
Pages : 216
Get Book
Book Description
As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.
Author: B.L. Rapoport
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318068195
Category : Medical
Languages : en
Pages : 109
Get Book
Book Description
Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy
Author: Christian Manegold
Publisher:
ISBN: 9783837412567
Category : Lungs
Languages : en
Pages : 190
Get Book
Book Description
